Research programme: therapeutics - NeuroTransit
Latest Information Update: 04 Aug 2016
At a glance
- Originator NeuroTransit
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Metabolic disorders; Neurological disorders
Most Recent Events
- 04 Aug 2016 Preclinical trials in Neurological disorders in USA (unspecified route)
- 04 Aug 2016 Preclinical trials in Metabolic disorders in USA (unspecified route)
- 04 Aug 2016 Preclinical trials in Cancer in USA (unspecified route)